To,
Lian-Sheng Ma, Science Editor, Company Editor-in-Chief, Editorial Office
Baishideng Publishing Group Inc
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: l.s.ma@wjgnet.com

Regarding: Manuscript NO.: 67699, “Renoprotective Role of Amlodipine in Patients with Hypertensive Chronic Kidney Disease”.

Dear Editor,

The authors thank the editorial board from The World Journal of Nephrology for their time and valuable suggestions for enhancing the scientific value and readability of the above-mentioned manuscript. Please find our point-by-point responses to the editorial board comments.

We hope we have fully addressed the concerns, and that the manuscript will now be considered suitable for publication.

Please feel free to contact me if needed.

Thank you,
Dr. Mohammed Yunus Khan,
doctorkhan26@gmail.com
Authors’ Responses to Editorial Board Comments

*Journal:* The World Journal of Nephrology  
*Manuscript NO.:* 676699

The authors have addressed comments below, thank you.

**Comment 1:** The age-standardized global prevalence of CKD was higher in women and girls (9.5%) than in men and boys (7.3%) and nearly one-third of CKD cases were in China (132.3 million) and India (115.1 million). “The prevalence of CKD in India is limited, and since the eGFR estimating equation and the Modification of Diet in Renal Disease formula have not been validated.” These two sentences seem to be inconsistent, in which, the prevalence of CKD in India is limited, what is the specific meaning of the message?

**Response:** For comment 1: We have revised this in the manuscript.

**Comment 2:** Pay attention to the formatting issues of the manuscript, e.g., lines 147-158 on page 4.

**Response:** For comment 2: Please see highlighted yellow section, we have corrected the formatting.

**Comment 3:** The content of “Blood Pressure Control in CKD” is too little, so it is suggested that the author narrate it from many aspects.

**Response:** For comment 3: Please see highlighted in yellow, we have edited the title to reflect accuracy.
**Comment 4:** The article has mentioned many times the single action and synergistic drug use, can we simply expand it?

**Response:** Please see highlighted in yellow.

**Comment 5:** The article mentions “Emergent Role of CCBs in Patients with HTN and CKD”, and the authors may consider adding the description of DHP-CCBs.

**Response:** Please see highlighted in yellow we have added the details. Thanks.

**Comment 6:** The authors suggest that “amlodipine - the only CCB” is not a rigorous statement.

**Response:** We have updated the manuscript to clarify this. Highlighted in yellow.

**Comment 7:** More detailed description of the Accomplish Trial, Sakura Trial, and ASCOT-BPLA Trial is recommended.

**Response:** We have made these changes. Please see highlighted.

**Comment 8:** It is suggested that the author should make a proper outlook in the conclusion.

**Response:** We have updated this. Please see highlighted.
Science Editor comments:

**Comment 1:** The authors did not provide original pictures. Please provide the original figure documents. Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor.

**Response:** We have uploaded accordingly.

**Comment 2:** PMID and DOI numbers are missing in the reference list. Please provide the PubMed numbers and DOI citation numbers to the reference list and list all authors of the references. Please revise throughout

**Response:** We have updated accordingly.

**Comment 3:** If an author of a submission is re-using a figure or figures published elsewhere, or that is copyrighted, the author must provide documentation that the previous publisher or copyright holder has given permission for the figure to be re-published; and correctly indicating the reference source and copyrights

**Response:** No figures have been re-used. Thank you.